Citi analyst Joel Beatty raised his price target for Amarin to $25 from $17 and maintains a Buy rating on the shares. The analyst increased his 2025 Vascepa sales projection to $3.0B from $2.3B and his sales multiple to 4.25 times from 3.75. The market is still underestimating how easy it will be for primary care docs to prescribe Vascepa, Beatty tells investors in a research note. While a debt offering and ramp up in the size of the sales force could pressure the stock due to investors perceiving an acquisition of Amarin as being less likely in the near-term, growth in scripts and sales should mitigate the downside, the analyst contends.